Table 4.

Prevalence of Human Immunodeficiency Virus Drug Resistance Among Participants With Virologic Failure During Efavirenz-Based Antiretroviral Therapy

HIV Genotype Prior to Initiation of EFV-Based ART (n = 189)a	No. (%) Wild-type at Virologic Failure	No. (%) Drug Resistant at Virologic Failure	Odds Ratio (95% CI)
Wild-type (n = 159)b	89 (55.2)	63 (44.8)	Reference
Drug-resistant (n = 29)c	3 (10.3)	25 (89.7)	11.6 (3.33–62.8)***

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; HIV, human immunodeficiency virus.

^aOne (0.9%) specimen was not sequenced prior to EFV-based ART initiation.

^bSeven (5.0%) specimens were not sequenced at virologic failure.

^cOne (3.0%) specimen was not sequenced at virologic failure.

^*** P < .0001 by Fisher exact test.